2-溴-1-(2-乙氧基苯基)-乙酮 | 152074-07-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(2-乙氧基苯基)-乙酮
• 英文名称: 2-bromo-2'-ethoxyacetophenone
• 英文别名: 2-bromo-1-(2-ethoxyphenyl)ethan-1-one；2-bromo-1-(2-ethoxyphenyl)ethanone；ω-bromo-2-ethoxyacetophenone
• CAS: 152074-07-2
• 化学式: C₁₀H₁₁BrO₂
• mdl: MFCD07785846
• 分子量: 243.1
• InChiKey: APYWRCOHDUNRLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  2-溴-1-(2-乙氧基苯基)-乙酮 在 lithium aluminium tetrahydride 、 sodium carbonate 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 [2-(2-Ethoxyphenyl)imidazo[1,2-a]pyridin-7-yl]methanol
  参考文献：
  名称：

  Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents

  摘要：

  Free fatty acid receptor 1 (FFA1 or GPR40) has been studied for many years as a target for the treatment of type 2 diabetes mellitus. In order to increase potency and reduce hepatotoxicity, a series of novel compounds containing imidazo[1,2-a]pyridine scaffold as GPR40 agonist were synthesized. Compound I-14 was identified as an effective agonist as shown by the conspicuous drop in blood glucose in normal and diabetic mice. It had no risk of hepatotoxicity compared with TAK-875. Moreover, good pharmacokinetic (PK) properties of I-14 were observed (CL = 27.26 ml/h/kg, t1/2 = 5.93 h). The results indicate that I-14 could serve as a possible candidate to treat diabetes.

  DOI：

  10.1016/j.bmc.2020.115574
• 作为产物：
  描述：

  乙氧基苯乙酮 在 溴 作用下， 以 乙醚 为溶剂， 以48%的产率得到2-溴-1-(2-乙氧基苯基)-乙酮
  参考文献：
  名称：

  [EN] NADPH OXIDASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND APPLICATION THEREOF
  [FR] INHIBITEURS DE LA NADPH OXYDASE, COMPOSITION PHARMACEUTIQUE LES COMPRENANT ET APPLICATION DE CEUX-CI

  摘要：

  本公开涉及一种式I的化合物，或其几何异构体、对映体、二对映体、消旋体、扭曲异构体、药用可接受的盐、前药或溶剂。本公开进一步涉及包含式(I)化合物的组合物。本文描述的化合物和组合物可用于抑制NADPH氧化酶活性。

  公开号：

  WO2019246343A1

文献信息

• Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists
  作者：Terry Rosen、Arthur A. Nagel、James P. Rizzi、Jeffrey L. Ives、June B. Daffeh、Alan H. Ganong、Karen Guarino、James Heym、Stafford McLean

  DOI：10.1021/jm00172a006

  日期：1990.10

  A novel structural class of highly potent and selective 5-HT3 receptor antagonists is described. The compounds in this new series contain a thiazole moiety linking an aromatic group and a nitrogen-containing basic region; the thiazole group appears to be acting as a carbonyl bioisostere in this system. An optimized member of this series, 4-(2-methoxyphenyl)-2-[[4(5)-methyl-5(4)-imidazolyl]methyl]thiazole

  描述了高效和选择性的5-HT 3受体拮抗剂的新型结构类别。这个新系列的化合物包含连接芳族基团和含氮碱性区域的噻唑部分；噻唑基似乎在该系统中充当羰基生物等排体。该系列的优化成员4-（2-甲氧基苯基）-2-[[[4（5）-甲基-5（4）-咪唑基]甲基]噻唑（5）在Bezold-Jarisch反射范例中表现出口服活性与标准药物恩丹西酮（1）和ICS-205-930（2）相当或更好。根据5-HT3受体结合的计算机药效团模型，合理化了一些构效关系。
• [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014057435A1

  公开（公告）日：2014-04-17

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物，其中R和环A1、A2和A3如描述中所述，以及其药用盐，其制备方法，含有一个或多个公式(I)化合物的药物组合物，以及它们作为药物的用途，特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
• [EN] NADPH OXIDASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND APPLICATION THEREOF<br/>[FR] INHIBITEURS DE LA NADPH OXYDASE, COMPOSITION PHARMACEUTIQUE LES COMPRENANT ET APPLICATION DE CEUX-CI
  申请人：TAIWANJ PHARMACEUTICALS CO LTD

  公开号：WO2019246343A1

  公开（公告）日：2019-12-26

  The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.

  本公开涉及一种式I的化合物，或其几何异构体、对映体、二对映体、消旋体、扭曲异构体、药用可接受的盐、前药或溶剂。本公开进一步涉及包含式(I)化合物的组合物。本文描述的化合物和组合物可用于抑制NADPH氧化酶活性。
• Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions
  申请人：Burgos Alain

  公开号：US20070055068A1

  公开（公告）日：2007-03-08

  A process for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes, wherein a metal borohydride, a Lewis base and an inorganic acid ester are brought together and an optically active amino alcohol and optionally a halide are then added. The compound obtained is a complex that is useful as a catalyst in asymmetric reduction reactions. The reaction is performed by adding the substance to be reduced, particularly prochiral ketones or ether oximes, in order to synthesize chiral alcohols or chiral amines.

  一种用于原位制备从氧杂硼烷硼酸盐复合物中衍生的手性化合物的方法，其中将金属硼氢化物、路易斯碱和无机酸酯混合，然后加入手性活性氨基醇和可选的卤化物。所得化合物是一种复合物，可用作不对称还原反应中的催化剂。通过将待还原物质，特别是原始手性酮或醚肟加入以合成手性醇或手性胺来执行反应。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。